Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Axiom Biotechnologies Inc.

Division of Sequenom Inc.
www.axiombio.com

Latest From Axiom Biotechnologies Inc.

Perlegen: Will Numbers Enable Pharmacogenomics

Until now, Perlegen contends, pharmacogenomics has failed to deliver because no one has had the statistical power to show connections. With its whole genome scanning technology, Perlegen aims to prove that it can come up with usable and predictive markers of drug response by inexpensively screening for millions of SNPs and analyzing subsequent patterns--even without any significant biological understanding. The start-up aims to use its technology to help compounds win regulatory approval and more market share than they otherwise could. Perlegen also plans to support in-licensed drug candidates and seek disease genes. It wants a share of drug sales its studies enable, and to leverage all the IP it can capture. Absent its own drug discovery and development program, Perlegen needs partners to provide the compounds and clinical samples with which it can create pharmacogenomic data and secure an FDA imprimatur. Competitors argue that smaller sets of data, informed by a clearer biological understanding, will provide equally effective pharmacogenomic data, cheaper.
BioPharmaceutical Strategy

Screening the Screeners

A host of start-ups want to make high-volume screening the method of choice for finding drug leads and for discovering the uses for those new, mysterious targets pouring out of the genetic databases, But few of the new firms are basing their long-term plans on screening services; most are either using their systems to look for their own drugs or still evolving their business plans along with their technologies.
BioPharmaceutical Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sequenom Inc.
  • Senior Management
  • Pandi Veerapandian, PhD, Pres. & CEO
    Robert R Lorifice, VP, Fin.
    Damien J Dunnington, PhD, VP, Discovery Research
  • Contact Info
  • Axiom Biotechnologies Inc.
    Phone: (858) 455-4500
    3550 General Atomics Ct.
    San Diego, CA 92121-1194
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register